Acceleration of aneurysm healing by controlled release of basic fibroblast growth factor with the use of polyethylene terephthalate fiber coils coated with gelatin hydrogel.
OBJECTIVE
The aims of this study were to develop an endovascular delivery system containing gelatin hydrogels for the controlled release of basic fibroblast growth factor (bFGF) with the use of polyethylene terephthalate fiber coils and to analyze whether such a system would promote healing in an experimental aneurysm.


METHODS
Carotid aneurysms were constructed in 66 rabbits with venous pouches. The polyethylene terephthalate fiber coils coated with and without gelatin hydrogels with different water volumes containing 0, 10, 50, and 100 microg bFGF were implanted into the aneurysms. Histological specimens were harvested at 1, 2, and 3 weeks and at 6 months after implantation. A histological evaluation was performed while the area occupied by the fibrosis in the aneurysms was calculated.


RESULTS
Three weeks after the application of the coils coated with gelatin hydrogels (95 vol%) containing 100 microg bFGF, all aneurysmal orifices were completely closed with neointima. When the coils coated with gelatin hydrogel (98 vol%) containing 100 microg bFGF were used, the orifices in three of the six aneurysms were closed. In contrast, the orifice of the aneurysm was not obliterated when other materials were used. After implanting the coils coated with gelatin hydrogel (95 vol%) containing 100 microg bFGF more than 3 weeks later, the aneurysm was histologically suffused with fibrous tissue, and the area occupied by fibrosis was significantly larger than that observed in the other groups (P < 0.05).


CONCLUSIONS
Local, controlled release of sufficient amounts of bFGF with polyethylene terephthalate fiber coils coated with gelatin hydrogel accelerated the organization of aneurysms.
Hatano
Taketo
T
Department of Neurosurgery and Clinical Research Unit, Kyoto National Hospital, Kyoto, Japan.
Miyamoto
Susumu
S
Kawakami
Osamu
O
Yamada
Keisuke
K
Hashimoto
Nobuo
N
Tabata
Yasuhiko
Y
D000783:Aneurysm / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D000818:Animals; D002340:Carotid Artery Diseases / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000379:methods*; D004343:Drug Implants / Q000008:administration & dosage / Q000627:therapeutic use; D004621:Embolization, Therapeutic / Q000379:methods*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000627:therapeutic use*; D005780:Gelatin / Q000008:administration & dosage / Q000627:therapeutic use*; D020100:Hydrogels / Q000008:administration & dosage / Q000627:therapeutic use*; D011093:Polyethylene Terephthalates / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
D020099:Coated Materials, Biocompatible; D003692:Delayed-Action Preparations; D004343:Drug Implants; D020100:Hydrogels; D011093:Polyethylene Terephthalates; D016222:Fibroblast Growth Factor 2; D005780:Gelatin